EcoDrugPlus

Cholecystokinin B Receptor

Ensembl ID : ENSHBUG00000003612
Gene Symbol: CCKBR
3 Cross references
191 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSHBUG00000019390
Gene Symbol: LOC102299385
2 Cross references
193 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSHBUG00000013946
Gene Symbol: LOC102311639
2 Cross references
242 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSHBUG00000015625
Gene Symbol: LOC102298587
2 Cross references
242 Possible Orthologues:

Cholesterol 24-Hydroxylase-Like

Ensembl ID : ENSHBUG00000014007
Gene Symbol: LOC102306044
2 Cross references
240 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSHBUG00000019121
Gene Symbol: CETP
3 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSHBUG00000022117
Gene Symbol: CHRM3
3 Cross references
186 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSHBUG00000002078
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSHBUG00000004229
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSHBUG00000002093
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Muscarinic 2a

Ensembl ID : ENSHBUG00000011351
Gene Symbol: CHRM2A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSHBUG00000017320
Gene Symbol: CHRM5A
1 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).